| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019362662 |
| P356 | DOI | 10.1038/SJ.GT.3302272 |
| P698 | PubMed publication ID | 15085175 |
| P5875 | ResearchGate publication ID | 8618506 |
| P2093 | author name string | Inoue M | |
| Hasegawa M | |||
| Yamamoto T | |||
| Nagai Y | |||
| Iida A | |||
| Fujikawa S | |||
| Kinoh H | |||
| Tokusumi Y | |||
| Washizawa K | |||
| P2860 | cites work | A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. | Q27470119 |
| Efficient selection for high-expression transfectants with a novel eukaryotic vector | Q27860810 | ||
| Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase | Q27860943 | ||
| Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 | ||
| A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression | Q33808044 | ||
| Recombinant Newcastle disease virus as a vaccine vector | Q33850246 | ||
| Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen | Q33850281 | ||
| The plasminogen activation system in tumor growth, invasion, and metastasis | Q34008816 | ||
| Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis | Q34013787 | ||
| Viral oncolysis | Q34124473 | ||
| Replication-selective virotherapy for cancer: Biological principles, risk management and future directions | Q34297058 | ||
| Cytolytic viruses as potential anti-cancer agents | Q34528247 | ||
| Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma | Q36116282 | ||
| Nontransmissible virus-like particle formation by F-deficient sendai virus is temperature sensitive and reduced by mutations in M and HN proteins | Q39733557 | ||
| A New Sendai Virus Vector Deficient in the Matrix Gene Does Not Form Virus Particles and Shows Extensive Cell-to-Cell Spreading | Q39752502 | ||
| Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease–substrate interaction | Q40653941 | ||
| An improved method for recovery of F-defective Sendai virus expressing foreign genes from cloned cDNA. | Q40721712 | ||
| Protease-dependent virus tropism and pathogenicity | Q40733009 | ||
| Host cell proteases controlling virus pathogenicity | Q40742881 | ||
| New developments in the virus therapy of cancer: a historical review | Q40745867 | ||
| Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector | Q40783262 | ||
| Efficient gene transfer to airway epithelium using recombinant Sendai virus. | Q40856925 | ||
| Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells | Q41908223 | ||
| Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense | Q44322076 | ||
| Sendai virus vector-mediated gene transfer of glial cell line-derived neurotrophic factor prevents delayed neuronal death after transient global ischemia in gerbils | Q45722935 | ||
| An oncolytic measles virus engineered to enter cells through the CD20 antigen | Q45729228 | ||
| Association of ganglioside-protein conjugates into cell and Sendai virus. Requirement for the HN subunit in viral fusion | Q45797517 | ||
| Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. | Q45886071 | ||
| Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis | Q48520992 | ||
| Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. | Q51841717 | ||
| Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer. | Q55344764 | ||
| A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases | Q68059709 | ||
| Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides | Q71319110 | ||
| Metastatic and non-metastatic colorectal cancer (CRC) cells induce host metalloproteinase production in vivo | Q73141313 | ||
| Oncolytic viruses | Q78595329 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Sendai virus | Q1055751 |
| P304 | page(s) | 1137-1145 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases | |
| P478 | volume | 11 |
| Q39955752 | A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon |
| Q35111983 | Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors |
| Q36202610 | Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1 |
| Q92356810 | Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes |
| Q33911962 | Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism. |
| Q40137396 | Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas |
| Q45388374 | Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. |
| Q66680337 | Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus |
| Q36761849 | Matrix metalloproteases: underutilized targets for drug delivery |
| Q35721486 | Mechanisms of Oncolysis by Paramyxovirus Sendai |
| Q39924299 | Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines |
| Q35861936 | Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency |
| Q35861933 | Oncolysis by paramyxoviruses: preclinical and clinical studies. |
| Q37990940 | Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions |
| Q55366271 | Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study). |
| Q26825239 | Oncolytic Sendai virus-based virotherapy for cancer: recent advances |
| Q34059067 | Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines |
| Q38008023 | Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm? |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q47552296 | Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA Damaging Agents: Implications for Oncolytic Virus Therapy |
| Q33619238 | Paramyxovirus entry and targeted vectors for cancer therapy |
| Q37191007 | Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded |
| Q38363535 | Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics |
| Q34183374 | Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-β gene. |
| Q39413447 | Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma |
Search more.